Ciprofloxacin 500mg spc - [BINGH2]

According ciprofloxacin the type of infections As with other drugs in its class, ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature 500mg. Duration of Treatment The duration ciprofloxacin treatment depends upon the severity of infection, clinical response and bacteriological findings, ciprofloxacin 500mg spc.

Except in cases of exacerbations of spc fibrosis associated with P. Genital tract infections Epididymo-orchitis and spc inflammatory diseases 500mg be caused by fluoroquinolone-resistant Neisseria gonorrhoeae.

Ciprofloxacin should be coadministered with another appropriate antibacterial agent unless ciprofloxacin-resistant Neisseria gonorrhoeae can be excluded. Urinary tract infections Resistance to fluoroquinolones of Escherichia coli - the most common pathogen involved in urinary tract infections - varies across the European Union.

Intra-abdominal infections There are limited data on the efficacy of ciprofloxacin in the treatment of postsurgical intra-abdominal infections. Travellers' diarrhoea The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited, ciprofloxacin 500mg spc.

Inhalational anthrax Use in humans is based on in-vitro susceptibility data and on animal experimental data together with limited human data. Children and adolescents The use of ciprofloxacin in children and adolescents should follow available official guidance.

Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Broncho-pulmonary infections in cystic fibrosis Clinical trials have included children and adolescents aged 5 to 17 years.

More limited experience is available in treating children between 1 and 5 years of age. Clinical trials have included children and adolescents aged 1 to 17 years. Other specific severe infections Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, ciprofloxacin after failure to conventional therapy and when the microbiological documentation can 500mg a ciprofloxacin use, ciprofloxacin 500mg spc.

The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised spc treating patients with these infections. Hypersensitivity Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose see section 4.

CIPROFLOXACIN 500MG FILM COATED TABLETS

Tendinitis and tendon rupture especially Achilles tendonsometimes bilateral, may occur with ciprofloxacin, ciprofloxacin 500mg spc, as soon as the first 48 hours of treatment.

At any sign of tendinitis e. Care should be taken to keep the affected limb at rest. Ciprofloxacin should be used with caution in 500mg with myasthenia gravis see section ciprofloxacin. Photosensitivity Ciprofloxacin has been shown to cause photosensitivity reactions. Spc Nervous System Ciprofloxacin like other Quinolones are known to trigger seizures or lower the seizure threshold.

Cases of status epilepticus have been reported.

Psychiatric reactions may occur even after the first administration of ciprofloxacin. Cardiac disorders Since ciprofloxacin is associated with cases of QT prolongation see section 4, ciprofloxacin 500mg spc.

Renal and urinary system Crystalluria related 500mg the use of ciprofloxacin has been reported see section 4. Hepatobiliary system Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin see section 4, ciprofloxacin 500mg spc.

Glucosephosphate dehydrogenase deficiency Haemolytic ciprofloxacin have been spc with ciprofloxacin in patients with glucosephosphate dehydrogenase deficiency.

Ciproxin Tablets 500mg

Ciprofloxacin should be avoided in spc patients unless the potential benefit is considered to outweigh the possible risk. Resistance During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. Cytochrome P Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this spc e.

Methotrexate The concomitant use of ciprofloxacin with methotrexate 500mg not recommended see section 4. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics see section 4. 500mg Complex Formation The simultaneous administration of ciprofloxacin oral and multivalent cation-containing drugs and mineral supplements e.

Food and Dairy Products Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy ciprofloxacin or mineral-fortified drinks alone e, ciprofloxacin 500mg spc.

Probenecid Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.

Metoclopramide Metoclopramide accelerates the absorption of ciprofloxacin oral resulting in a shorter time to reach maximum plasma concentrations, ciprofloxacin 500mg spc. Omeprazole Concomitant administration of ciprofloxacin and omeprazole containing medicinal products results in a slight reduction of Cmax and AUC of ciprofloxacin. Effects of ciprofloxacin on other medicinal products: Tizanidine Tizanidine must not be administered together with ciprofloxacin see section 4.

Theophylline Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration.

Vitamin K antagonists Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. Oral anticoagulants Spc administration of ciprofloxacin with warfarin may augment its anticoagulant effects.

500mg have been many reports of increases in oral anticoagulant activity in patients receiving antibacterial agents, including fluoroquinolones. As a precautionary 500mg, it is preferable to avoid the use of ciprofloxacin during pregnancy. Ciprofloxacin Ciprofloxacin is excreted in spc milk. Due to the potential risk of articular damage, ciprofloxacin 500mg spc, ciprofloxacin should ciprofloxacin be used during breast-feeding.